NeOnc Technologies Holdings Inc. reported a net loss of $8.6 million, or $0.45 per diluted share, for the third quarter of 2025, compared to a net loss of $2.2 million, or $0.12 per diluted share, in the same period last year. General and administrative expenses increased to $903,000 from $244,000, while research and development expenses decreased to $715,000 from $957,000. During the period, the company advanced its NEO100 and NEO212 clinical programs, received $2.5 million in NIH STTR grants, expanded into the Middle East through new partnerships, and acquired advanced AI and 3D bioprinting intellectual property.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576355-en) on November 14, 2025, and is solely responsible for the information contained therein.